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Abstract
Background: Both adenoviral and lentiviral vectors have been successfully used to induce bone repair by over-
expression of human bone morphogenetic protein 2 (BMP-2) in primary rat bone marrow stromal cells in pre-
clinical models of ex vivo regional gene therapy. Despite being a very efficient means of gene delivery, there are
potential safety concerns that may limit the adaptation of these viral vectors for clinical use in humans.
Recombinant adeno-associated viral (rAAV) vector is a promising viral vector without known pathogenicity in
humans and has the potential to be an effective gene delivery vehicle to enhance bone repair. In this study, we
investigated gene transfer in rat and human bone marrow stromal cells in order to evaluate the effectiveness of
the self-complementary AAV vector (scAAV) system, which has higher efficiency than the single-stranded AAV
vector (ssAAV) due to its unique viral genome that bypasses the rate-limiting conversion step necessary in ssAAV.
Methods: Self-complementaryAAV2 encoding GFP and BMP-2 (scAAV2-GFP and scAAV2-BMP-2) were used to
transduce human and rat bone marrow stromal cells in vitro, and subsequently the levels of GFP and BMP-2
expression were assessed 48 hours after treatment. In parallel experiments, adenoviral and lentiviral vector
mediated over-expression of GFP and BMP-2 were used for comparison.
Results: Our results demonstrate that the scAAV2 is not capable of inducing significant transgene expression in
human and rat bone marrow stromal cells, which may be associated with its unique tropism.
Conclusions: In developing ex vivo gene therapy regimens, the ability of a vector to induce the appropriate level
of transgene expression needs to be evaluated for each cell type and vector used.
Background
The healing of large bone defects presents a challenge
for regenerative medicine. Autologous bone grafting is
the current gold standard to promote bone repair, but
in many cases there is insufficient amounts of autolo-
gous bone graft available to heal the defect. In addition,
there is morbidity associated with bone graft harvest [1].
Recombinant human BMP-2 (rhBMP2) and BMP-7
(rhBMP7) are two osteoinductive agents that are pre-
sently available for clinical use. RhBMP-2 is FDA
approved for use in anterior spinal fusion and open
tibial shaft fractures [2]. RhBMP-7 (OP-1) was shown to
have comparable efficacy to autologous bone grafting in
the treatment of tibial non-unions without the donor
site morbidity [3]. Nevertheless, these recombinant pro-
teins are expensive and require supraphysiologic doses
to achieve the desired clinical effect [4]; there are also
concerns that these high doses are associated with side
effects such as soft tissue edema or heterotopic bone
formation [5,6]. Therefore, there has been interest in
developing gene therapy as a strategy to deliver proteins
to a specific bone repair site, particularly in cases where
there are large bone defects or defects associated with
severe soft tissue injury.
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The use of viral vectors that over-express BMP-2 has
been successful in promoting bone repair in a variety of
pre-clinical animal models of bone defect healing [7-10].
In previous studies of ex vivo gene therapy in our labora-
tory, lentiviral and adenoviral mediated over-expression
of BMP-2 in rat bone marrow stromal cells successfully
healed a critical sized rat femoral defect [11-13]. Overex-
pression of BMP-2 by lentiviral transduction induced
superior quality of bone repair compared to adenoviral
transduced cells as noted in biomechanical testing and
u-CT bone volumetric data [13].
Safety is a critical issue in identifying the appropriate
viral vector for human use. Since gene therapy for bone
repair would be used to treat a non-lethal condition,
any increase in morbidity or mortality would not be
acceptable. Insertional mutagenesis and emergence of
replication competent viral particles remain areas of
concern with respect to lentiviral vectors and the safety
of these vectors needs to be evaluated in human trials
[14,15]. The adenoviral vector does not integrate into
the host chromosomes and the potential risk of inser-
tional mutagenesis is less than the lentiviral vectors [16].
However, adenoviral vectors induce strong cellular and
humoral immune responses in the host that results in
tissue injury and loss of transgene expression [16-18].
Recombinant adeno-associated viral (AAV) vector is a
small non-enveloped single-stranded DNA virus [19].
This unique viral vector has the distinct advantage
of being capable of infecting a wide range of host cell
types including dividing and non-dividing cells [20]. In
addition, there is no conclusive evidence indicating
pathogenicity of AAV vector in humans [21]. AAV also
induces long-term gene expression in transduced
cells and its persistence is thought to be mostly extra-
chromosomal [16,21]. The lower risk of random geno-
mic integration of AAV in comparison with other viral
vectors is considered to be a safety advantage [21,22].
Several studies have also shown very low cell-mediated
immunogenicity of AAV that could facilitate the long-
term expression of the transgene [23-25]. A number of
AAV serotypes have been used as delivery methods in
gene therapy and each serotype has a distinct affinity for
certain cell types that is because of differences in cell
binding and/or intracellular trafficking [21]. AAV2 is the
most widely used serotype in human clinical trials and
has a broad range of tissue tropism in several species
[21]. A number of clinical trials have been approved by
the FDA to assess AAV2 in treatment of a variety of
human diseases including inflammatory arthritis, cystic
fibrosis, alpha-1 antitrypsin deficiency, epilepsy, hemo-
philia B, Parkinson’s disease and muscular dystrophies
[26]. The aim of this study was to evaluate the efficacy
of a self-complementary AAV2 vector system in
transducing human and rat bone marrow stromal cells
in comparison with lentiviral and adenoviral vectors.
Methods
Viral Vector Production
AAV plasmids (double-stranded, serotype 2) encoding
rhBMP-2 and enhanced GFP (eGFP) cDNA under CMV
promoter were constructed, respectively (Figure 1A).
The serotype 2 of AAV viruses (AAV-BMP-2 and AAV-
eGFP) were produced according to the method pre-
viously described [27]. The AAV particles were purified
by CsCl density gradient ultracentrifugation. The AAV
viral genomes were quantified by DNA dot blot and
were in the range of 1 × 1012 to 5 × 1012 viral genomes/
ml according to a previously published protocol [28].
Lentiviral vectors encoding BMP-2 and eGFP cDNA
under RhMLV promoter (LV-BMP-2 and LV-GFP) were
generated by calcium phosphate-mediated co-transfec-
tion of plasmids in 293T cells as previously described
(Figure 1B) [29]. Lentiviral particles were concentrated
100-fold by ultracentrifugation. The titer of eGFP-
expressing lentiviral vector was determined by infection
of 293T cells, followed by flow cytometric analysis of
the percentages of eGFP-positive cells. The titer of
BMP-2-expressing vector was estimated by comparison
of p24 levels with eGFP-expressing vector. The titers of
lentiviral vectors were in the range of 1 × 108 to 3 × 108
transducing units/ml.
Adenoviral vectors encoding BMP-2 and eGFP cDNA
under the CMV promoter (Ad-BMP-2 and Ad-GFP)
were prepared as previously described (Figure 1C) [30].
Adenoviral vectors were propagated in 293 cells and cell
lysates were concentrated by CsCl density gradient
ultracentrifugation. Viral stocks were subsequently puri-
fied by dialysis in phosphate buffered saline (PBS) (Invi-
trogen, Carlsbad, CA, USA) containing 10% glycerol.
The titers of adenoviral vectors were in the range of 5 ×
109 to 1 × 1010 transducing units/ml.
Cell preparation and transduction with AAV, lentiviral and
adenoviral vectors
Institutional approval for the use of rats to harvest bone
marrow cells was obtained from the University of Con-
necticut Health Center animal care committee. The
bone marrow cells were harvested from 8 week-old
male Lewis rats (Charles Rivers Labs Inc. Wilmington,
MA, USA). The rats were euthanized using CO2
asphyxiation and the primary rat bone marrow cells
were collected from the femurs and the tibias by flush-
ing the medullary canal with Iscove’s Modified Dulbec-
co’s Medium (IMDM) (Invitrogen, Carlsbad, CA, USA).
The cells were maintained in IMDM containing 15%
fetal bovine serum (FBS) (Omega Scientific, Tarzana,
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CA, USA), 100 U/ml penicillin and 100 mg/ml strepto-
mycin sulfate until they reached passage three.
Human bone marrow stromal cells which were CD45
negative and CD90, CD105 and CD146 positive [31]
(Gift of Pamela Robey, National Institute of Dental and
Craniofacial Research, Bethesda, MD. USA) were main-
tained in Minimum Essential Medium (MEM) Alpha
Medium (Invitrogen, Carlsbad, CA, USA) containing
20% FBS, 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin sulfate.
One million rat and human bone marrow stromal
cells and 293T cells (ATCC, Manassas, VA, USA) were
transduced with LV-BMP-2 or LV-GFP in the presence
of polybrene for 24 hours at MOI of 25. Transduction
of one million rat and human bone marrow stromal
cells and 293T cells with AAV-BMP-2 and AAV-GFP
was carried out using105 viral genomes/cell in serum
free media for 1 hour and another 23 hours in regular
media. One million rat and human bone marrow stro-
mal cells and 293T cells (ATCC, Manassas, VA, USA)
were transduced with Ad-BMP-2 or Ad-GFP in serum
free media for 4 hours at MOI of 100, which was then
replaced by regular media and maintained for 20 more
hours. In all transduction protocols, the culture media
was replaced by fresh media after the first 24 hours and
the assessment of BMP-2 production or eGFP expres-
sion was carried out 24 hours after the addition of the
fresh media. Since transduction with each viral vector
was done at the specified MOI and 1 million cells were
used in all experiments, the number of viral particles of
each vector was the same in the experiments.
ELISA for BMP-2
In vitro BMP-2 production induced by AAV-BMP-2,
Ad-BMP-2 or LV-BMP-2 transduced cells during a 24-
hour period was quantified by a commercial enzyme
linked immunosorbent assay (ELISA) kit (Quantikine,
R&D, Minneapolis, MN, USA) according to the manu-
facturer’s protocol. Briefly, one million rat bone marrow
stromal cells or 293T cells were plated into 10-cm cul-
ture dishes. 24 hours after transduction the medium was
replaced by 10 ml of fresh medium. Cells were incu-
bated for another 24 hours after which culture superna-
tants were harvested for BMP-2 measurement. The
BMP-2 production was measured in triplicate and
reported as nanograms of BMP-2/one million cells/24 h.
Figure 1 Schematic Drawings of the Viral Vectors A) AAV vector that consists of inverted terminal repeats (ITR) at 3’ and 5’ ends with BMP-2
or GFP under the control of CMV promoter and SV40 poly(A), B) Lentiviral vector that consists of long terminal repeats (LTR) with RhMLV
promoter driving the expression of BMP-2 or GFP and C) Adenoviral vector that consists of ITRs and BMP-2 or GFP under the control of CMV
promoter as well as SV40 poly(A). The adenoviral vector carries deletions in E1 and E3 regions rendering it replication deficient except in 293 cell
lines (including 293T cells) that are capable of substituting E1 function, hence the toxicity of this vector to 293T cells. ψ: packaging signal, cppt:
central polypurine tract, RRE: Rev-responsible element, SV40 poly(A): simian virus poly adenilation signal sequence.
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Fluorescent Microscopy
The visualized GFP expression in transduced cells was
detected under fluorescent microscopy (Nikon Eclipse
TE2000-U, Nikon Instruments Inc., Melville, NY, USA)
at two days after transduction. The cell images were
taken by SPOT advanced software (Diagnostic Instru-
ments, Inc., Sterling Heights, MI, USA).
Statistical Analysis
Student t-test was used to compare BMP-2 levels
induced by viral vectors in human and rat bone marrow
stromal cells and 293T cells. P values less than 0.05
were considered significant.
Results
GFP expression in the human and rat bone marrow
stromal cells transduced with AAV2-GFP, LV-GFP and Ad-
GFP
293T cells were used as a control for GFP expression in
transduced human and rat bone marrow stromal cells.
The scAAV2-GFP showed strong GFP expression in
transduced 293T cells 48 hours post-infection, but in
human and rat bone marrow stromal cells it did not
show GFP expression as strongly as transduced 293T
cells at the same time point. In contrast, strong GFP
expression was detectable in all three cell types trans-
duced with LV-GFP. Ad-GFP transduced human and rat
bone marrow stromal cells showed strong GFP expres-
sion, too. Although the surviving Ad-GFP transduced
293T cells did show strong levels of GFP expression, the
majority of the adenoviral transduced 293T cells had
died by 48 hours secondary to the adenoviral toxicity to
these cells (Figure 2).
BMP-2 production by the rat bone marrow stromal cells
transduced with the AAV-BMP-2, LV-BMP-2 and Ad-BMP-2
BMP-2 production in 1 million transduced 293T or rat
bone marrow stromal cells was quantified by ELISA
using the culture supernatants harvested 24 hours after
addition of fresh medium.
In 293T cells which were used as a control cell line,
BMP-2 production was induced by all three of the viral
vectors. BMP-2 levels were approximately 47% higher in
293T cells transduced with AAV-BMP-2 (79.61 ± 4.14
ng) compared to those transduced with LV-BMP-2
(53.96 ± 5.21 ng), (P < 0.05). BMP-2 production by Ad-
BMP-2 transduced 293T cells (28.59 ± 0.64 ng) showed
a dramatic decrease and was only 35% of the levels
achieved by AAV group. The low BMP-2 production by
adenoviral transduced cells was due to the fact that ade-
noviral particles are known to be toxic to 293T cells
(Figure 3A).
In rat bone marrow stromal cells, Ad-BMP-2 and
LV-BMP-2 induced high levels of BMP-2 production
(146.1 ± 5.1 ng and 90.8 ± 3.2 ng, respectively) whereas
AAV-BMP-2 did not produce any detectable amount of
BMP-2 production at 105 viral genomes/cell, (P < 0.05)
(Figure 3B).
Collectively, the self-complementary AAV2 system
used in these experiments was not capable of inducing
adequate levels of gene expression in either the rat or
human bone marrow cells in comparison to the lenti-
viral and adenoviral vector systems.
Discussion
In this study we performed a comparison between three
vector systems (LV, AV, and AAV) that are commonly
used in gene therapy approaches to over express BMP-2
or GFP in human and rat bone marrow stromal cells.
We used a scAAV2 vector in our experiments and
sought to determine its potential utility in our ex vivo
gene therapy approach for bone repair. The results of
the present study showed that scAAV2 produced signifi-
cantly less BMP-2 in rat bone marrow stromal cells
compared to lentiviral and adenoviral vectors. In con-
trast to the observation by Pagnotto et al [32] in which
scAAV2 in human bone marrow mesenchymal stem
cells showed high efficiency of gene transfer, the level of
GFP expression in human bone marrow stromal cells in
our study was not as strong as lentiviral and adenoviral
transduced cells after 48 hours of transduction. These
results suggest that careful screening of transgene
expression by different viral vectors in different cell
types is necessary to develop successful strategies for
gene therapy.
Different AAV serotypes have been used to transduce
different cell types [20,33,34]. Goodrich et al [35]
screened serotypes1-6 and 8 of scAAV vectors and
showed superior capacity of scAAV2 to induce gene
expression in equine chondrocytes and synoviocytes.
Wang et al [36] reported successful gene delivery using
AAV serotype 8 into cardiac and skeletal muscle cells of
mice and hamsters. In contrast, AAV serotype 2 was
not capable of transducing these cell types efficiently
due to its unique tropism.
In a mouse model of gene therapy for hemophilia B,
the use of AAV8 and AAV9 resulted in a much higher
expression levels of Factor IX compared with lentiviral
gene delivery to hepatocytes [37]. Our results demon-
strate higher BMP-2 expression by AAV-BMP-2 in
293T cells compared to the other viral vectors. This
shows the usefulness of the AAV vector system if the
appropriate target cells can be efficiently transduced.
Several investigators have successfully used AAV vec-
tors to transduce human cells such as human islet cells,
CD34 positive peripheral blood progenitor cells and
mesenchymal stromal cells [38-40]. Lattermann et al
[41] indicated cell-type specific tropism for AAV vector
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in an experiment where human nucleus polposus (hNP)
cells, synovial fibroblasts and bone marrow derived cells
were transduced with ssAAV-Luc and Ad-Luc. AAV
transduced bone marrow-derived cells and synovial
fibroblasts showed significantly lower luciferase expres-
sion compared to hNP cells. In contrast, when Ad-Luc
was used, human bone marrow derived cells had com-
parable luciferase expression to hNP cells. Although we
used scAAV2 that has shown a higher efficiency com-
pared to ssAAV vector, our results with AAV-GFP and
Ad-GFP transduction of human bone marrow cells were
similar to this study.
293T
Rat 
BMSCs
Human
BMSCs
Non-transduced AAV-GFP                LV-GFP               Ad-GFP
Figure 2 GFP Expression in Viral Transduced Cells 1 million rat and human bone marrow stromal cells (BMSCs) and 293T cells were
transduced with AAV-GFP, LV-GFP and Ad-GFP and the GFP expression was assessed 48 hours after transduction. Non-transduced cells served as
negative control. In comparison with the non-transduced controls, AAV-GFP transduced 293T cells show strong eGFP expression, but rat and
human bone marrow stromal cells (BMSCs) did not exhibit expression levels as strong as 293T cells. LV-GFP and Ad-GFP transduced cells showed
strong GFP expression in all transduced cell types except for Ad-GFP transduced 293T cells in which the viral replication causes cell death.
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Figure 3 BMP-2 Production by Viral Transduced Cells 1 million rat bone marrow stromal cells (BMSCs) and 293T cells were transduced with
AAV-BMP-2, LV-BMP-2 and Ad-BMP-2 and the BMP-2 production was quantified 48 hours after transduction. Non-transduced cells served as
negative control. A) Amongst the three viral vectors used to over express BMP-2, AAV-BMP-2 induced the highest amount of BMP-2 production
in 293T cells. Transducing the 293T cells with Ad-BMP-2 induced cell death after 24 hours in culture. B) AAV-BMP-2 transduced rat bone marrow
stromal cells (BMSCs) did not produce any detectable amount of BMP-2 as opposed to LV-BMP-2 and Ad-BMP-2 transduced rat bone marrow
stromal cells which made significantly higher amounts of BMP-2.*: P value < 0.05 compared to all other groups, †: P value < 0.05 compared to
non-transduced group.
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The genome of single stranded AAV vector has to be
converted to double-stranded replicative form once it
has entered the target cells, which is a rate limiting step
in the replicative cycle of AAV [42,43]. Double-stranded,
self-complementary AAV vectors bypass this step and
provide the opportunity to achieve more efficient trans-
duction [44]. McMahon et al [45] reported that rat bone
marrow cells were unable to produce high levels of GFP
when transduced with different titers of single-stranded
AAV (ssAAV) serotypes 1,2,4,5 and 6. AAV2 still had
the highest efficiency compared to the other serotypes.
Thus, we hypothesized that a self-complementary dou-
ble-stranded AAV2 would have higher transduction effi-
ciency for the human and rat bone marrow stromal
cells. Nevertheless, our results with double-stranded
AAV-BMP-2 and AAV-GFP also showed the relative
inefficiency of the scAAV2 in transducing human and
rat bone marrow stromal cells. Our speculation is that
low transduction efficiency may be due to a scarcity of
cell surface receptors for AAV in this particular cell
type or a defect in nuclear trafficking of the vector
sequence.
Membrane-associated heparan sulfate proteoglycan
serves as the primary cell receptor for AAV type 2 [46].
This accounts for the broad host range of AAV vector.
Cross-packaging the AAV2 genome into several AAV
serotypes has revealed that the viral tropism to different
cell lines in rodents, monkeys and humans could be
related to their affinity for heparan sulfate [47]. These
reports further support our observations that rat bone
marrow cells may be resistant to transduction by AAV2
due to lack of certain AAV receptors.
Testing MOIs of 1, 10, 100, 1000 and 10,000, Stender
et al [48] found the MOI of 104 to result in the highest
transgene expression of AAV2-eGFP transduced human
bone marrow derived mesenchymal stem cells, but
reported severely restricted expression levels compared
to 293 cells. Selection of the optimum MOI for trans-
duction of rat bone marrow stromal cells with lentiviral
and adenoviral vectors and AAV for transduction of
human bone marrow stromal cells was based on the
previously published articles in our lab and elsewhere
[12,29,32]. As for the AAV, an additional experiment
was done using 104 viral genomes/cell of AAV-BMP-2
in rat bone marrow stromal cells with results similar to
the higher MOI of 105 viral genomes/cell (data not
shown). However, the possibility of a different MOI
being more effective can not be ruled out.
Striated muscle cells are known to be effectively trans-
duced by the AAV vectors [36]. Direct injection of a
doxycycline controllable AAV-BMP-2 vector [49] into
the hind limb muscle of mice was reported to induce
ectopic bone formation likely due to transduction of the
muscle cells. In addition, injection of the vector into a
CD1 nude mouse calvarial defect loaded with human
MSCs demonstrated some bone formation in the defect
site, but not complete bone healing. Other reports of
coating structural allografts with various AAV vectors
[50-52] have indicated success in allograft integration
and bone healing in mice via increased vascularization
and remodelling (rAAV-RANKL and rAAV-VEGF) and
increased bone formation (rAAV-caALK2 and rAAV2.5-
BMP-2). The authors hypothesized that a mixed popula-
tion of cells including MSCs, inflammatory cells and
osteoblasts were the potential local cell targets for
the AAV vector. Kang et al [53] reported in vitro and
in vivo bone formation using human adipose-derived
mesenchymal stem cells transduced with ssAAV2 to
over express BMP-7. These studies also highlight the
impact of cell type on the development of a successful
gene therapy strategy using AAV to promote bone
repair.
AAV transduction efficiency in fibroblasts has been
shown to be species dependent [54] and the underlying
mechanism for inefficient transduction of murine fibro-
blasts is thought to be due to impaired trafficking into
the nuclei of the transduced cells [55]. These reports
show that more extensive efforts are needed to optimize
the AAV vector for rat and human bone marrow stro-
mal cell transduction by modifying the viral envelope or
the steps involved in nuclear trafficking.
Conclusions
In summary, our data showed that the serotype 2 of
self-complementary AAV vector system was unable to
induce sufficient levels of transgene expression in both
human and rat bone marrow stromal cells. To our
knowledge this is the first report on BMP-2 production
by a scAAV vector system in primary rat bone marrow
stromal cells. Our results demonstrate the influence of
cell type on the potential efficacy of different gene ther-
apy strategies that can be used for bone repair and high-
lights the need for further experiments to understand
and overcome the barriers of transduction with AAV in
human and rat bone marrow stromal cells.
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